Literature DB >> 526432

The carcinogenicity of 15,16-dihydro-11-methyl-cyclopenta[a]phenanthren-17-one.

M M Coombs, T S Bhatt, S Young.   

Abstract

Direct comparison of skin-tumour induction by 15,16-dihydro-11-methylcyclopenta[a]phenanthren-17-one (I) and by benzo[a]pyrene on mouse skin, both by repeated application or by initiation with a single dose followed by promotion with croton oil, demonstrated that these two carcinogens have similar potency. After repeated application of (I) the mean latent period for skin-tumour induction was linearly related to the logarithm of the dose over a 10-fold dose range. Under these conditions, application of the aryl-hydrocarbon-hydroxylase inhibitor 7,8-benzoflavone together with (I) inhibited tumour induction by about 40%. By contrast, in the 2-stage experiment, little effect on tumour incidence or latent period was observed when this inhibitor was applied with the single initiating dose of (I). Co-administration of the epoxide-hydratase inhibitor 1,1,1-trichloropropene oxide caused enhancement by shortening the latent period. After s.c. injection of (I) into mice, a similar number of tumours was induced on skin remote from the site of injection by promotion with corton oil begun either one week or 6 months after initiation. Gastric instillation of (I) into female rats induced mammary adenocarcinomas.

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 526432      PMCID: PMC2010134          DOI: 10.1038/bjc.1979.285

Source DB:  PubMed          Journal:  Br J Cancer        ISSN: 0007-0920            Impact factor:   7.640


  15 in total

1.  Development of adenocarcinoma of the breast in the Wistar rat following the gastric instillation of methylcholanthrene.

Authors:  H SHAY; E A AEGERTER
Journal:  J Natl Cancer Inst       Date:  1949-10       Impact factor: 13.506

2.  Induction of microsomal aryl hydrocarbon (3,4-benzo(alpha)pyrene) hydroxylase and cytochrome P-450K in rat kidney cortex. I. Characteristics of the hydroxylase system.

Authors:  R Grundin; S Jakobsson; D L Cinti
Journal:  Arch Biochem Biophys       Date:  1973-10       Impact factor: 4.013

3.  Early differential effects of 3-methylcholanthrene and its "K-region" epoxide on mouse skin. Possible implication in the two-stage mechanism of tumorigenesis.

Authors:  K Bürki; J E Wheeler; Y Akamatsu; J E Scribner; G Candelas; E Bresnick
Journal:  J Natl Cancer Inst       Date:  1974-10       Impact factor: 13.506

4.  High-pressure liquid chromatographic analysis of benzo(alpha)pyrene metabolism and covalent binding and the mechanism of action of 7,8-benzoflavone and 1,2-epoxy-3,3,3-trichloropropane.

Authors:  J K Selkirk; R G Croy; P P Roller; H V Gelboin
Journal:  Cancer Res       Date:  1974-12       Impact factor: 12.701

5.  Potentially carcinogenic cyclopenta(a)phenanthrenes. VI. 1,2,3,4-Tetrahydro-17-ketones.

Authors:  M M Coombs; T S Bhatt
Journal:  J Chem Soc Perkin 1       Date:  1973

6.  Identification of the proximate and ultimate forms of the carcinogen 15,16-dihydro-11-methylcyclopenta[a]phenanthren-17-one.

Authors:  M M Coombs; A M Kissonerghis; J A Allen; C W Vose
Journal:  Cancer Res       Date:  1979-10       Impact factor: 12.701

7.  The relationship between metabolism, DNA binding, and carcinogenicity of 15,16-dihydro-11-methylcyclopenta(alpha)phenanthren-17-one in the presence of a microsomal enzyme inhibitor.

Authors:  M M Coombs; T S Bhatt; C W Vose
Journal:  Cancer Res       Date:  1975-02       Impact factor: 12.701

8.  Evaluation of survival data and two new rank order statistics arising in its consideration.

Authors:  N Mantel
Journal:  Cancer Chemother Rep       Date:  1966-03

9.  Mutagenicity and cytotoxicity of benzo(a)pyrene benzo-ring epoxides.

Authors:  A W Wood; P G Wislocki; R L Chang; W Levin; A Y Lu; J Yagi; O Hernandez; D M Herina; A H Conney
Journal:  Cancer Res       Date:  1976-09       Impact factor: 12.701

10.  Lack of initiating activity in mutagens which are not carcinogenic.

Authors:  M M Coombs; T S Bhatt
Journal:  Br J Cancer       Date:  1978-07       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.